Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

New treatment avenues in squamous cell carcinoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.07.17
Views: 835

Dr Luis Raez - Memorial Cancer Institute, Hollywood (FL), USA

Dr Raez speaks with ecancer at NOSCM 2017 about treatment options for squamous cell carcinoma (SCC).

He discusses immunotherapies are providing an alternative to chemotherapy, noting the approvals for nivolumab and pembrolizumab in second and first line cases, and highlights the OAK study of atezolizumab as showing a clear benefit for SCC patients.

Dr Raez also considers investigational targets, including PI3K and FGFR, and describes the design of the Lung MAP trial, taking place in clinics across America.

Dr Raez also spoke with ecancer about lung cancer advances at the Best of ASCO 2017 meeting in Miami.

Related videos

follow us

ONJ e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence